KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018)

Historic Non-Current Deferred Tax Liability for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Q4 2018 value amounting to $1.2 million.

  • Amneal Pharmaceuticals' Non-Current Deferred Tax Liability fell 6416.18% to $1.2 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.2 million, marking a year-over-year decrease of 6416.18%. This contributed to the annual value of $1.2 million for FY2018, which is 6416.18% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Non-Current Deferred Tax Liability of $1.2 million as of Q4 2018, which was down 6416.18% from $1.8 million recorded in Q3 2018.
  • Amneal Pharmaceuticals' Non-Current Deferred Tax Liability's 5-year high stood at $3.3 million during Q4 2017, with a 5-year trough of $1.2 million in Q4 2018.